Chemo funding shake-up

A dispute between the health department, pharmacists and other chemotherapy providers was sparked by significant reductions in PBS payments for drugs such as docetaxel, which went off patent in December.

Some chemotherapy providers used the inflated price the government paid them for docetaxel to cross-subsidise the cost of delivering it, the department said.

When the generic versions entered the market on 1 December, some providers complained it would not be possible to keep treating

Latest

Trending